Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) EBT Margin (2018 - 2025)

Historic EBT Margin for Catalyst Pharmaceuticals (CPRX) over the last 11 years, with Q3 2025 value amounting to 47.87%.

  • Catalyst Pharmaceuticals' EBT Margin rose 34200.0% to 47.87% in Q3 2025 from the same period last year, while for Sep 2025 it was 49.43%, marking a year-over-year increase of 84300.0%. This contributed to the annual value of 43.98% for FY2024, which is 202500.0% up from last year.
  • Catalyst Pharmaceuticals' EBT Margin amounted to 47.87% in Q3 2025, which was up 34200.0% from 47.28% recorded in Q2 2025.
  • Catalyst Pharmaceuticals' 5-year EBT Margin high stood at 54.33% for Q4 2022, and its period low was 37.03% during Q3 2023.
  • Moreover, its 5-year median value for EBT Margin was 44.45% (2024), whereas its average is 39.86%.
  • Per our database at Business Quant, Catalyst Pharmaceuticals' EBT Margin plummeted by -824600bps in 2023 and then surged by 814800bps in 2024.
  • Over the past 5 years, Catalyst Pharmaceuticals' EBT Margin (Quarter) stood at 33.45% in 2021, then soared by 62bps to 54.33% in 2022, then decreased by -22bps to 42.24% in 2023, then grew by 24bps to 52.31% in 2024, then dropped by -8bps to 47.87% in 2025.
  • Its EBT Margin stands at 47.87% for Q3 2025, versus 47.28% for Q2 2025 and 50.41% for Q1 2025.